Mark For: OPDIVO SULIBRA™ trademark registration is intended to cover the categories of pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use. [all]
Status
2021-07-21 UTC
LIVE APPLICATION Published for Opposition
A pending trademark application has been examined by the Office and has been published in a way that provides an opportunity for the public to oppose its registration.
(Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use
No
Current Use
No
Intent To Use
Yes
Filed ITU
Yes
44D Filed
No
44E Current
No
66A Current
No
Current Basis
No
No Basis
No
Attorney Name
Marilyn F. Kelly
Attorney Docket Number
00155842-US
Timeline
2020-06-03
Application Filed
2020-06-06
Location: NEW APPLICATION PROCESSING
2020-06-06
Status: Live/Pending
2020-06-06
Transaction Date
2021-04-06
Published
2021-06-01
Location: INTENT TO USE SECTION
2021-06-01
Status: Notice of Allowance (NOA) sent (issued) to the applicant. Applicant must file a Statement of Use or Extension Request within six
MARILYN F. KELLY BRISTOL-MYERS SQUIBB COMPANY P.O. BOX 4000 TRADEMARKS DEPT., MAILSTOP D4243 PRINCETON, NJ 08648-4000
Good, Services, and Codes
IC 005. US 005 006 018 044 046 051 052. G & S: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use
International Codes:
5
U.S. Codes:
006,018,044,046,051,052
Type Code
Type
GS0051
Pharmaceutical preparations for human use
Trademark Filing History
Description
Date
Proceeding Number
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2021-06-01
PUBLISHED FOR OPPOSITION
2021-04-06
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2021-04-06
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2021-03-17
ASSIGNED TO EXAMINER
2021-03-02
76145
APPROVED FOR PUB - PRINCIPAL REGISTER
2021-03-02
TEAS/EMAIL CORRESPONDENCE ENTERED
2021-03-01
88889
TEAS RESPONSE TO OFFICE ACTION RECEIVED
2021-02-26
CORRESPONDENCE RECEIVED IN LAW OFFICE
2021-02-26
88889
NOTIFICATION OF NON-FINAL ACTION E-MAILED
2020-09-03
6325
NON-FINAL ACTION WRITTEN
2020-09-03
83704
NON-FINAL ACTION E-MAILED
2020-09-03
6325
ASSIGNED TO EXAMINER
2020-09-02
83704
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2020-06-24
NEW APPLICATION ENTERED IN TRAM
2020-06-06
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
OneLook
Acronym Finder
Bristol-Myers Squibb Company
Application
Drawing
| 